

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Canceled).

Claim 2. (Currently Amended) An isolated tumor antigen peptide of 9-11 ~~8-14~~ amino acids in length, which comprises a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43, and ~~which is a fragment of cyclophilin-B sequence of SEQ ID NO:44, and that~~ binds to an HLA HLA-A24 antigen and is recognized by cytotoxic T lymphocytes.

Claims 3-7. (Canceled).

Claim 8. (Currently Amended) An isolated tumor antigen peptide of 9-11 amino acids in length comprising a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43,

~~in which~~ wherein the amino acid residue located at position 2 ~~in the amino acid sequence shown in any one of SEQ ID Nos~~ in said SEQ ID NO: 1, 2, 41, 42, or 43 ~~1-11~~ is substituted by

tyrosine, phenylalanine, methionine, or tryptophan, and/or

the amino acid residue located at the C-terminus position in
said SEQ ID NO: 1, 2, 41, 42, or 43 is substituted by
phenylalanine, leucine, isoleucine, tryptophan, or methionine,
and

wherein said peptide binds to HLA-A24 antigen and is
recognized by cytotoxic T lymphocytes.

Claims 9-11. (Canceled).

Claim 12. (Currently Amended) A composition comprising as
an active ingredient at least one of substances selected from
tumor antigen peptides according to any one of claims 2 or 8 ~~2,~~
~~4, 8, or 10.~~

Claims 13-25. (Canceled).